Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$4.91 USD
+0.04 (0.82%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.90 -0.01 (-0.20%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
AUPH 4.91 +0.04(0.82%)
Will AUPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AUPH
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
Other News for AUPH
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals to Present at Investor Conference
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
Aurinia Pharmaceuticals Announces Q1 Results Date